1. Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan.
- Author
-
Kamata, Kazuhiro, Jindai, Kazuaki, Ichihara, Nao, Saito, Hiroki, Kato, Hideaki, Kunishima, Hiroyuki, Shintani, Ayumi, Nishida, Osamu, and Fujitani, Shigeki
- Subjects
- *
MEDICAL personnel , *EMERGING infectious diseases , *COVID-19 pandemic , *PANDEMICS , *CLINICAL trials - Abstract
REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF